Full Press Release Details
Biopharma to Present at VirtualInvestorConferences.com
Online Event on March 5, 2015
TEL-AVIV, Israel, March 3, 2015 RedHill
Biopharma Ltd. (NASDAQ/TASE: RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily
focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including
gastrointestinal cancers, today announced that Guy Goldberg, RedHill's Chief Business Officer, will be presenting at VirtualInvestorConferences.com,
a live and interactive online event,
on Thursday, March 5, 2015, at 10:00 am EST.
Mr. Goldberg will provide an overview of
RedHill's business and anticipated key milestones for 2015. The VirtualInvestorConferences.com presentation is a real-time
event where participants are invited to ask questions online in both the presentation hall as well as in the RedHill Biopharma
"virtual trade booth".
RedHill's live presentation will be available
through the Company's website at: http://ir.redhillbio.com/events.cfm. A subsequent
archived replay of the presentation will be made available for a period of 30 days on the Company's website.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE:
RDHL) is an emerging Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage, proprietary,
orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.
RedHill's current pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for
the treatment of Helicobacter pylori infection, with an ongoing first Phase III study; (ii) RHB-104 - an oral
combination therapy for the treatment of Crohn's disease, with an ongoing first Phase III study; (iii) BEKINDA
(RHB-102) - a once-daily oral pill formulation of ondansetron with a Phase III study in the U.S. for acute gastroenteritis
and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted in December
2014; (iv) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v)
MESUPRON - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and
other solid tumor cancers; (vi) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage
Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (vii) RIZAPORT
(RHB-103) - an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA currently under discussions
with the FDA and a European marketing application submitted in October 2014; and (viii) RHB-101 - a once-daily oral
pill formulation of the cardio drug carvedilol.
About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com,
created by BetterInvesting (NAIC) and PR Newswire has been the only monthly virtual investor conference series that provides an
interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel
of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing
and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by
the words "intends," "may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress
and results of the Company's research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate
development efforts; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully
complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be
required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other
regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance
of the Company's therapeutic candidates; (v) the Company's ability to establish and maintain corporate collaborations;
(vi) the interpretation of the properties and characteristics of the Company's therapeutic candidates and of the results
obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (vii) the implementation of the Company's
business model, strategic plans for its business and therapeutic candidates; (viii) the scope of protection the Company is able
to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business
without infringing the intellectual property rights of others; (ix) parties from whom the Company licenses its intellectual property
defaulting in their obligations to the Company; (x) estimates of the Company's expenses, future revenues capital requirements
and the Company's needs for additional financing; and (xi) competitive companies and technologies within the Company's
industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report
on Form 20-F filed with the SEC on February 26, 2015. All forward-looking statements included in this Press Release are made only
as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required